
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc is positioned for growth, particularly with the anticipated increase in market share and revenues from its POSLUMA PSMA PET imaging product, projected to rise from low to mid-single-digit share levels to high-single-digit share levels by the end of 2025. The introduction of a new Pylarify formulary, which increases batch size by approximately 50% and includes three years of TPT eligibility, is expected to rejuvenate growth in the Pylarify product line beginning in 2026. Additionally, the potential growth contributions from non-PYL segments could further enhance overall revenue and margin performance, driving better-than-expected earnings per share growth in 2026 and 2027.
Bears say
Lantheus Holdings Inc. is experiencing a decline in its growth profile, with projections for 2025-2026 indicating slower growth compared to its profitable small to mid-cap MedTech peers. The company's Pylarify product generated revenues of $260 million, reflecting an 8% year-over-year decrease and falling approximately $14 million short of consensus expectations, which has raised concerns among investors. Additionally, the lower-than-anticipated unit growth of just 2% year-over-year, coupled with a significant 10% pricing headwind, further exacerbates the negative outlook for Lantheus's financial performance.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares